Flag of the European Union EU Clinical Trials Register Help

Clinical trials for PUVA

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44356   clinical trials with a EudraCT protocol, of which   7382   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    57 result(s) found for: PUVA. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2006-004519-23 Sponsor Protocol Number: 08/08 Start Date*: 2009-03-19
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik für Dermatologie
    Full Title: Comparison of fumaric acid ester-PUVA versus PUVA-etretinate in palmoplantar pustolosis
    Medical condition: Psoriasis pustulosis palmoplantaris
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004741-27 Sponsor Protocol Number: DM14/11351 Start Date*: 2015-02-18
    Sponsor Name:University of Leeds
    Full Title: Comparison of Alitretinoin with PUVA as the first line treatment in patients with severe chronic hand eczema
    Medical condition: Severe chronic hand eczema
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10066558 Chronic eczema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-003701-24 Sponsor Protocol Number: 21011 Start Date*: 2004-12-10
    Sponsor Name:E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER
    Full Title: A RANDOMISED, OPEN-LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF BEXAROTENE (TARGRETIN) CAPSULES COMBINED WITH PUVA, COMPARED TO PUVA TREATMENT ALONE IN PATIENTS WITH MYCOSIS FUNGOIDES.
    Medical condition: CUTANEOUS T CELL LYMPHOMA.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-001236-23 Sponsor Protocol Number: IMP 25300 Start Date*: 2004-11-23
    Sponsor Name:Serono International S.A.
    Full Title: A multicentre, open label Phase IIIb/IV study of subcutaneously administered efalizumab in the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respon...
    Medical condition: Adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant of other systemic therapies including cyclosporin...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10037153 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) CZ (Completed) DK (Completed) SE (Completed) ES (Completed) SK (Completed) AT (Completed) IE (Completed) IT (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004243-29 Sponsor Protocol Number: 27809 Start Date*: 2008-05-23
    Sponsor Name:Merck Serono International SA. An Affiliate of Merck KGaA, Darmstadt, Germany
    Full Title: A Phase IV open label study in moderate to severe chronic plaque psoriasis subjects transitioning from previous systemic antipsoriasis therapies (methotrexate, cyclosporine, retinoids or PUVA, NBUV...
    Medical condition: Adult subjects with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including cyclosporin...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004227-37 Sponsor Protocol Number: 27808 Start Date*: 2008-02-25
    Sponsor Name:Merck Serono S.A. - Geneva
    Full Title: A Phase IV multicentre, randomised, double-blind, placebo controlled, trial to evaluate the safety and efficacy of Raptiva ® in the treatment of subjects with moderate to severe plaque psoriasis in...
    Medical condition: Subject with chronic (disease history of at least 6 months from diagnosis) moderate to severe plaque psoriasis involving the hands and/or feet (PGA – H&F ratings of 3 or 4) at screening, who have f...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) BE (Completed) ES (Completed) FR (Completed) IT (Prematurely Ended) GB (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000212-28 Sponsor Protocol Number: M-PUVA2012 Start Date*: 2012-06-20
    Sponsor Name:Medizinische Universität Graz, Univ. Klinik für Dermatologie
    Full Title: A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage Ia to IIb.
    Medical condition: mycosis fungoides
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028503 Mycosis fungoides stage I PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028504 Mycosis fungoides stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018279-99 Sponsor Protocol Number: HUM07-066 Start Date*: 2010-05-05
    Sponsor Name:Faculty of Medicine, Otto-von-Guericke-University Magdeburg
    Full Title: Skin Topoproteome under Adalimumab (Humira®) Treatment in Patients with Moderate to Severe Psoriasis
    Medical condition: Disease under investigation: Adult patients of both genders with moderate to severe chronic plaque psoriasis who failed to respond to or who have a contraindication to, or are intolerant to other s...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001952-32 Sponsor Protocol Number: ACA-NETH-07-14 Start Date*: 2008-11-07
    Sponsor Name:Radboud University Nijmegen Medical Centre - Department of Dermatology
    Full Title: The effect of adalimumab on immune markers in lesional psoriatic skin.
    Medical condition: Plaque psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-004547-35 Sponsor Protocol Number: IMP27330.1 Start Date*: 2007-01-10
    Sponsor Name:Serono GmbH
    Full Title: Phase IV study to investigate neutrophil downregulation of Thy-1 by Raptiva® (Efalizumab) as a potential responder predictor in patients with moderate to severe plaque psoriasis
    Medical condition: Moderate to severe chronic plaque psoriasis (PASI ≥ 12) failing to respond to, or with a contraindication to, or intolerant to other systemic therapies including cyclosporine, methotrexate and Psor...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000480-25 Sponsor Protocol Number: ROCAC Start Date*: 2006-08-24
    Sponsor Name:Investigator Trondheim Hudlegesenter AS
    Full Title: Classification and characterization of patient suffering from moderate to severe plaque psoriasis responding to subcutaneous administered efalizumab
    Medical condition: Plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    4.0 10050577 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-006126-10 Sponsor Protocol Number: Efalizumab in CTCL Start Date*: 2008-11-27
    Sponsor Name:Charité - University Hospital Berlin
    Full Title: pilot study to evaluate the efficacy of Efalizumab in patients with cutaneous t-cell lymphoma
    Medical condition: The cutaneous T-cell lymphoma (also known as Sézary syndrome) is a common disorder of proliferated cells with characteristics of maligne t-lymphocytes immigrating from the cutaneous blood vessels t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006309-96 Sponsor Protocol Number: 0881A6-3326 Start Date*: 2007-06-08
    Sponsor Name:Wyeth Pharmaceuticals France
    Full Title: A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study to Explore and Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept (Etanercept Autoinjecto...
    Medical condition: PSORIASIS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SE (Completed) NL (Completed) DK (Completed) BE (Completed) FI (Completed) ES (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2004-002629-36 Sponsor Protocol Number: 0881A6-101764 Start Date*: 2005-02-01
    Sponsor Name:Wyeth Pharmaceuticals, Global Medical Affairs Department
    Full Title: A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects with Psoriasis
    Medical condition: psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) SE (Completed) IE (Completed) DK (Completed) FI (Completed) CZ (Completed) DE (Completed) GB (Completed) IT (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-000924-11 Sponsor Protocol Number: CTCL Start Date*: 2015-06-17
    Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculty Mannheim represented by the chancellor
    Full Title: Phase IIA Study on therapy with the NF-kB inhibiting and apoptosis inducing drug dimethylfumarate (DMF) in Patients with Cutaneous T cell lymphoma.
    Medical condition: Cutaneous T cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028508 Mycosis fungoides/Sezary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023901-36 Sponsor Protocol Number: UHK-GMD-LOA-04 Start Date*: 2011-04-12
    Sponsor Name:Faculty of Medicine, Otto-von-Guericke-University, Magdeburg
    Full Title: Psoriasis-topoproteome under ustekinumab treatment (PIROUETTE-Study) - as an interventional observation study (phase IV) within approved label and indication and with minimal invasive taking of ski...
    Medical condition: STELARA™ as IMP will be used in all relevant aspects (indication, contraindications, dosing) completely within the approved label, namely for the treatment of adult patients with moderate to severe...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001724-12 Sponsor Protocol Number: 0881A6-4425 Start Date*: 2008-06-20
    Sponsor Name:Wyeth Pharmaceuticals France
    Full Title: Estudio aleatorizado y en doble ciego, dirigido a evaluar la eficacia y la seguridad de etanercept 50 mg dos veces a la semana y etanercept 50 mg una vez a la semana en el tratamiento de la psorias...
    Medical condition: Psoriasis en placa de grado moderado a severo Moderate to severe plaque psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) BE (Completed) DE (Completed) AT (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2016-001531-12 Sponsor Protocol Number: LRP/LNP1955/2016/003 Start Date*: 2016-08-16
    Sponsor Name:Lupin Limited
    Full Title: A Phase II, Dose Ranging, Exploratory Clinical Study to Assess the Efficacy, Pharmacodynamics, and Safety of LNP1955 in Patients with Moderate-to-Severe Plaque Psoriasis
    Medical condition: Moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000018190 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-006227-31 Sponsor Protocol Number: 0881X1-4503 Start Date*: 2009-01-09
    Sponsor Name:Medical Faculty, Otto-von-Guericke-University Magdeburg
    Full Title: Inflammatory Topoproteome of Psoriasis under Etanercept Treatment
    Medical condition: Patients with a severe psoriasis will be treated with Enbrel (Etanercept) 2 x 50 mg s.c. per week over 12 weeks (n = 6 patients). The treatment follows rigorously the approved label of the drug. Th...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004465-41 Sponsor Protocol Number: P04612 Start Date*: 2006-01-27
    Sponsor Name:SCHERING-PLOUGH
    Full Title: A multi-center, open-label trial evaluating the Efficacy, Safety and the Impact on Quality of Life of Infliximab Therapy in patients with moderate to severe psoriasis not responding and/or intolera...
    Medical condition: Moderate to severe psoriasis.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Aug 20 10:47:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA